VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (“MBI”) (TSX Venture: MBI) is pleased to announce the appointment of Erinn B. Broshko as Chief Executive Officer and a director of MBI.

Prior to joining MBI, Mr. Broshko was a corporate and securities lawyer with the Vancouver law firm of Farris, Vaughan, Wills & Murphy LLP. Mr. Broshko’s legal practice was focussed primarily on biotechnology companies. Mr. Broshko holds a B.A. (hons) and M.A. from the University of Saskatchewan, an LL.B. from Dalhousie Law School and an M.B.A. from the University of British Columbia.
“Erinn brings to MBI extensive business, legal and transactional experience and we welcome his involvement as MBI continues through its development stage. He is a team player with a proven track record of leadership and is intimately familiar with our company’s products and management”, said Dr. Nathan Yoganathan, MBI’s President and Chief Scientific Officer.

Mr. Broshko said, “I am enthusiastic about this opportunity because I believe that MBI can become a leader in molecular diagnostics. I intend to work with the rest of the management team and the board of directors to focus on delivering strong, consistent results for our shareholders.”

Corporate Matters

MBI has granted to certain of its directors, officers, employees and consultants five-year incentive stock options to purchase an aggregate of 3,075,000 common shares at an exercise price of $0.40 per share.

About Med BioGene

MBI is a biotechnology company with advanced research expertise in gene expression technology. MBI’s mission is to become a market leader in the supply of content for molecular-based diagnostic micro arrays. MBI intends to fulfill this mission by developing and marketing genetic content for molecular-based human diagnostic tests. Molecular diagnostics, based on genetic expression, is a developing technology field that has the potential to replace certain of today’s standard diagnostic tests. MBI intends to utilize its expertise in gene expression, bioinformatics and micro arrays to develop the diagnostic tests’ genetic content. From the tens of thousands of genes in the human genome, MBI is attempting to identify those genes, known as "bio markers," which mark the presence of various disease conditions.
MBI’s initial focus will be developing diagnostic tests for certain types of cancer, specifically lymphoma and leukemia. In the future, MBI intends to develop diagnostic tests to identify the earliest stages of heart disease or the presence of an infectious disease. These diagnostic test kits will be designed to provide additional information to physicians to allow them to create more suitable and more effective treatments for an improved patient prognosis.

For further information, please contact:

Dr. Nathan Yoganathan
Chairman, President and Chief Scientific Officer
(604) 827-5100
nathan@medbiogene.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements or information are only predictions based upon MBI’s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. Our forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.